What Could Send Eli Lilly Stock Soaring
Eli Lilly (LLY) has demonstrated significant rally potential, with multiple instances of its stock surging over 30% in under two months. Notably, it recorded more than 50% rallies twice, including key upswings in 2021 and 2025. These powerful gains highlight Eli Lilly’s capacity for rapid advances, suggesting that future catalysts could drive the stock to substantial new highs based on its strong historical performance.
Specifically, we see these catalysts:
- Accelerating Operating Margin Inflection
- Orforglipron (Oral GLP-1) Launch Unlocking New Market Stratum
- China GLP-1 Penetration Deepening via Localized Production
Catalyst 1: Accelerating Operating Margin Inflection
- Buy Or Sell Microsoft Stock At $425?
- Strong Q1 Says Marvell Is Becoming Broadcom’s Most Credible Rival
- Costco’s Premium Valuation Makes More Sense Than You Think
- AMD Stock: A Guidance Raise The Market Is Still Rewarding
- AVGO Stock: The Math Hidden In Its Price
- What Could Push MSFT Stock Higher From Here?
- Details: Driving Non-GAAP Performance Margin above 48%, Unlocking significant EPS upside beyond consensus
- Segment Affected: Company-Wide (driven by Cardiometabolic)
- Potential Timeline: Next 2-4 Earnings Calls
- Evidence: Performance margin expanding over 800bps YoY in recent quarters, Revenue growth significantly outpacing opex growth
Catalyst 2: Orforglipron (Oral GLP-1) Launch Unlocking New Market Stratum
- Details: Expanding Total Addressable Market for obesity treatment, Adding potential $10B+ peak sales franchise
- Segment Affected: Diabetes and Obesity
- Potential Timeline: Mid-2026
- Evidence: CFO confirms commercial readiness for launch upon FDA approval, Competitor’s next-generation injectable failed to show superiority
Catalyst 3: China GLP-1 Penetration Deepening via Localized Production
- Details: Accelerating revenue growth in a key undeveloped market, De-risking global supply chain for core growth drivers
- Segment Affected: International Business Unit
- Potential Timeline: Market re-rating in 2026, material revenue impact 2027+
- Evidence: Announced $3B investment to build local manufacturing capacity, Orforglipron marketing application already filed with NMPA in China
But The Stock Is Not Without Its Risks
Here are specific risks we see:
- GLP-1 Price War & Margin Erosion
- Bloating Inventory & Channel Stuffing Indicators
- Medicaid Rebate Calculation Liability
Looking at historical drawdown during market crises is another lens to look at risk.
LLY fell 43% in the Dot-Com crash, 51% in the Global Financial Crisis, and around 19-22% in the 2018, Covid, and Inflation shocks. Risk sticks around despite positives.
Reference: Current Fundamentals
- Revenue Growth: 44.7% LTM and 32.1% last 3-year average.
- Cash Generation: Nearly 9.2% free cash flow margin and 45.6% operating margin LTM.
- Valuation: Eli Lilly stock trades at a P/E multiple of 43.5
| LLY | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Pharmaceuticals | – |
| PE Ratio | 43.5 | 24.3 |
|
|
||
| LTM* Revenue Growth | 44.7% | 6.6% |
| 3Y Average Annual Revenue Growth | 32.1% | 5.5% |
|
|
||
| LTM* Operating Margin | 45.6% | 18.7% |
| 3Y Average Operating Margin | 37.9% | 18.2% |
| LTM* Free Cash Flow Margin | 9.2% | 14.2% |
*LTM: Last Twelve Months | If you want more details, read Buy or Sell LLY Stock.
Still not convinced about LLY stock? Consider Portfolio Approach
Portfolios Win When Stock Picks Fall Short
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
Beating the market consistently is hard, but the Trefis High Quality (HQ) Portfolio makes it look achievable. By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000. See how this curated selection delivers superior risk-adjusted returns in our detailed performance factsheet.